Eli Lilly and Company announced a multi-year collaboration with Nimbus Therapeutics. The partnership focuses on developing a novel preclinical oral obesity drug.
Lilly will pay Nimbus an upfront fee of $55 million. Nimbus is also eligible for up to approximately $1.3 billion. These payments cover potential development, commercial, and sales milestones.
The deal reinforces Lilly's focus on expanding its dominant weight-loss franchise and maintaining competitiveness against rivals such as Novo Nordisk. The partnership utilizes Nimbus's computational drug discovery platform to address unmet needs in obesity and other metabolic diseases.